- In July 2024, Sun Pharmaceutical Industries Limited announced that the U.S. Food and Drug Administration (FDA) had approved LEQSELVI (deuruxolitinib) 8 mg tablets for the treatment of adults with severe alopecia areata. LEQSELVI, a JAK inhibitor, targets the root cause of alopecia areata and has been clinically proven to provide statistically significant efficacy
- In June 2024, Equillium Inc. announced positive topline results from its Phase 2, single-dose, proof-of-concept (PoC) study of EQ101 in adult patients with moderate to very-severe alopecia areata (AA), an autoimmune condition where immune cells attack hair follicles, leading to hair loss
- In September 2023, Q32 Bio announced that the first patient had been dosed in a randomized, double-blind, placebo-controlled Phase 2 multicenter, proof-of-concept study to assess bempikibart in adult patients with severe alopecia areata. Q32 Bio and Horizon are collaborating on the development of bempikibart, a fully human anti-IL-7Rα antibody that helps re-regulate adaptive immune function by blocking signaling through both IL-7 and TSLP, two crucial immune pathways
- In June 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) had granted approval for LITFULO (ritlecitinib), a once-daily oral treatment for individuals aged 12 and older with severe alopecia areata. The recommended dosage for LITFULO is 50 mg. This marks it as the first and only FDA-approved treatment for adolescents (12+) suffering from severe alopecia areata
- In March 2023, Concert Pharmaceuticals announced the presentation of data from its Phase 3 clinical trial, THRIVE-AA2. The presentation showcased the results of the THRIVE-AA2 study, which evaluated the oral investigational drug deuruxolitinib in adult patients with moderate to severe alopecia areata, an autoimmune disorder that causes patchy or complete hair loss on the scalp
- In June 2022, Eli Lilly and Company and Incyte announced that the U.S. Food and Drug Administration (FDA) had approved OLUMIANT (baricitinib), a once-daily oral treatment, as the first systemic therapy for adults with severe alopecia areata (AA). The medication is available in 4-mg, 2-mg, and 1-mg tablets, with a recommended starting dose of 2 mg per day, which can be increased to 4 mg per day if the treatment response is insufficient
